RCMNY
CHRS icon

Rubric Capital Management (New York)’s Coherus Oncology CHRS Stock Holding History

Rubric Capital Management (New York)’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-867,800
Closed -$635K – 75
2025
Q2 		$635K Sell
867,800
-4,390,954
-83% -$3.79M 0.01% 65
2025
Q1 		$4.24M Hold
5,258,754
– – 0.08% 57
2024
Q4 		$7.26M Sell
5,258,754
-5,141,246
-49% -$5.77M 0.09% 59
2024
Q3 		$10.8M Hold
10,400,000
– – 0.18% 53
2024
Q2 		$18M Hold
10,400,000
– – 0.47% 47
2024
Q1 		$24.9M Buy
10,400,000
+10,004,793
+2,532% +$24.6M 0.73% 43
2023
Q4 		$1.32M Buy
+395,207
New +$1.06M 0.03% 56
2020
Q2 		– Sell
-1,583,061
Closed -$25.7M – 55
2020
Q1 		$25.7M Sell
1,583,061
-543,019
-26% -$10M 4.06% 7
2019
Q4 		$38.3M Buy
2,126,080
+88,550
+4% +$1.63M 4.33% 6
2019
Q3 		$41.3M Buy
2,037,530
+1,337,530
+191% +$26.7M 3.78% 5
2019
Q2 		$15.5M Sell
700,000
-1,940,771
-73% -$33.7M 1.22% 30
2019
Q1 		$36M Sell
2,640,771
-409,229
-13% -$5.46M 3.36% 11
2018
Q4 		$27.6M Buy
3,050,000
+2,420,000
+384% +$28M 3.42% 11
2018
Q3 		$10.4M Buy
630,000
+288,510
+84% +$5.11M 1.1% 31
2018
Q2 		$4.78M Sell
341,490
-121,906
-26% -$1.74M 0.47% 32
2018
Q1 		$5.12M Buy
+463,396
New +$5.07M 0.48% 42

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Rubric Capital Management (New York)'s CHRS Position: Q3 2025 in Review

Rubric Capital Management (New York) sold out of Coherus Oncology (CHRS) in Q3 2025, closing a stake of 867,800 shares — an estimated $635K sold.

Rubric Capital Management (New York) first reported a position in CHRS in Q1 2018 and held it in 16 quarters. The position peaked at $41.3M in Q3 2019. 114 funds tracked by Wall St. Rank hold CHRS as of Q3 2025.

  • Rubric Capital Management (New York) reported no remaining Coherus Oncology position as of Q3 2025 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 867,800 Coherus Oncology shares in Q3 2025, an estimated $635K.
  • Rubric Capital Management (New York) first reported a position in Coherus Oncology in Q1 2018 and held it in 16 quarters.
  • Rubric Capital Management (New York)'s Coherus Oncology position peaked at $41.3M in Q3 2019.
  • 114 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2025.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2025, filed 14 Nov 2025.